Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 9:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 75 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: pravastatin sodium Clear all

Conditions: Schizophrenia, Schizoaffective Disorders, Schizophreniform Disorders
Interventions: Pravastatin, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 68 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Nephrotic Syndrome, Hyperlipidemia
Interventions: Pravastatin; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 70 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Hematopoietic Stem Cell Transplant (HSCT), Endothelial Injury
Interventions: Pravastatin; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 2 Years to 25 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: End-Stage Renal Disease, Chronic Allograft Nephropathy
Interventions: Irbesartan, Pravastatin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2004
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Healthy Subjects
Interventions: Simvastatin, Pravastatin, Placebo; Drug · Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer, Other Solid Tumors
Interventions: IDE196, Binimetinib, Crizotinib; Drug
Lead sponsor: IDEAYA Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 12
States / cities: Los Angeles, California • San Francisco, California • Denver, Colorado + 9 more

Conditions: Progeria, Hutchinson-Gilford Syndrome
Interventions: Lonafarnib, Zoledronic Acid, Pravastatin; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: Not listed
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Preeclampsia
Interventions: Pravastatin, Placebo; Drug
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years and older · Female only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2024
U.S. locations: 3
States / cities: Chicago, Illinois • Pittsburgh, Pennsylvania • Galveston, Texas

Conditions: Healthy
Interventions: Pravastatin; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Healthy Volunteers
Interventions: BMS-986196, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, Pravastatin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Millcreek, Utah

Conditions: Progeria
Interventions: Lonafarnib, Zoledronic Acid, and Pravastatin; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: Not listed
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Fontan Circulation
Interventions: Sildenafil 10mg oral tablet (participants <20kg), or 20mg oral tablet (participants ≥20kg), Pravastatin 20 mg oral tablet (ages <13 years), or 40 mg oral tablet (≥14 years); Drug
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 8 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Hermansky-Pudlak Syndrome (HPS), Pulmonary Fibrosis, Oculocutaneous Albinism, Platelet Storage Pool Deficiency, Metabolic Disease
Interventions: Losartan, Zileuton, N-Acetylcysteine, Pravastatin, Erythromycin; Drug
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections, HIV Seronegativity, Lipodystrophy
Interventions: Pravastatin sodium, Simvastatin, Atorvastatin calcium, Nelfinavir mesylate, Efavirenz; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 10
States / cities: Stanford, California • Denver, Colorado • Baltimore, Maryland + 6 more

Conditions: Hypercholesterolemia
Interventions: ETC-1002, Placebo, Statin Therapy; Drug
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 40
States / cities: Muscle Shoals, Alabama • Chandler, Arizona • Chino, California + 36 more

Conditions: Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Refractory Anemia With Excess Blasts, Untreated Adult Acute Myeloid Leukemia
Interventions: pravastatin sodium, idarubicin, cytarabine, laboratory biomarker analysis; Drug · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 74 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: ADPKD, Autosomal Dominant Polycystic Kidney
Interventions: Pravastatin, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 25 Years to 60 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Combined Hyperlipidemia
Interventions: Pravafen, Pravastatin, Fenofibrate; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 481 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 57
States / cities: Phoenix, Arizona • Sierra Vista, Arizona • Long Beach, California + 46 more

Conditions: HIV Infections, Lipodystrophy
Interventions: Pravastatin sodium, Fenofibrate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 630 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2003
U.S. locations: 57
States / cities: Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 33 more

Conditions: Bile Salt Export Pump (BSEP) Transporter, Polysorbate 80
Interventions: pravastatin and chenodeoxycholic acid, after metformin and placebo, valacyclovir, chenodeoxycholic acid, and enalaprilat, after polysorbate 80 and placebo; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Lymphedema, Fibrosis
Interventions: Pravastatin, Pentoxifylline, Tocopherol; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 295 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy
Interventions: Embibatinib, Rabeprazole, Midazolam, Digoxin, Pravastatin, Montelukast, Omeprazole, Itraconazole, Warfarin, Rosuvastatin, Bosentan, Quinidine; Drug
Lead sponsor: Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 65 Years
Enrollment: 196 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Millcreek, Utah

Conditions: Atherosclerosis, Cardiovascular Disease
Interventions: any statin, niacin, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 65 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV Infections, Hyperlipidemia
Interventions: Pravastatin, Darunavir, Ritonavir, Washout; Drug · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 60 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Aurora, Colorado

Search by objective public record fields.

Effects of Pravastatin on Cholesterol, Inflammation and Cognition in Schizophrenia

Lipid Lowering Agents to Limit Lipid Oxidation and Activation of Clotting System in Nephrotic Syndrome

Pravastatin as a Prophylactic to Reduce Endothelial Injury in Pediatric Patients With Elevated Body Mass Index

Prevention of Kidney Transplant Rejection

Effect of Statin Use on Aldosterone Secretion

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

A Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria

Pravastatin for Prevention of Preeclampsia

Pravastatin 80 mg Tablets Dosed in Healthy Subjects Under Non-Fasting Conditions

A Study to Evaluate the Drug-drug Interaction Potential of BMS-986196 in Healthy Participants

Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria

IMProving DRug Dosing and Outcomes for Single VEntricle Patients With Fontan Associated Liver Disease

Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome

The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs

Evaluation of ETC-1002 vs Placebo in Patients Receiving Ongoing Statin Therapy

Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes

Statin Therapy in Patients With Early Stage ADPKD

A Study to Evaluate Daily Pravastatin, Fenofibrate or Pravafen in the Treatment of Combined Hyperlipidemia

Safety and Effectiveness of Fenofibrate and Pravastatin in HIV-Positive Patients With Abnormal Blood Lipids

Impact of Metformin and Polysorbate 80 on Drug Absorption and Disposition

Systemic Therapy of Open-label Prophylactic Pravastatin or Pentoxifylline/Tocopherol Prevention of Lymphedema Advancing to Eventual Fibrosis: an Interventional Registry-embedded Bayesian Randomized Trial for Radiation Sequelae (STOP4-LATE-FIBROSE)

A Clinical Trial to Evaluate MK-4208/Embibatinib in Healthy Adult Participants (MK-4208-001/Embibatinib-1014)

High-Density Lipoprotein (HDL) Cholesterol Increased Plaque Stabilization in the Elderly

Genetic Predictors of Variability in the Drug-drug Interaction Between Darunavir/Ritonavir and Pravastatin